Technical Analysis
BMY's stock shows a bearish trend in recent trading sessions, with RSI at 33.73 indicating oversold conditions. The stock is trading below its 20-day SMA of $57.81, suggesting downward momentum. The MACD indicator shows a bearish signal with -0.51.
News Impact Analysis
Recent positive developments:
However, the market appears to be focusing on broader challenges:
Price Forecast for Next Week
Based on technical indicators and Fibonacci levels:
Expected price range: $52.88 - $54.47
Trading Recommendation: SELL
Rationale:
Target exit points:
Risk factors:
Note: This analysis is based on technical indicators and recent market data. Investment decisions should consider your personal financial situation, risk tolerance, and investment objectives.
The price of BMY is predicted to go up -15.1%, based on the high correlation periods with GURE. The similarity of these two price pattern on the periods is 95.13%.
BMY
GURE
Bristol is launching several new cancer and immunology drugs that can have high sales trajectories, given the high unmet medical need.
Oncology drug Opdivo holds the potential to radically shift the treatment paradigm in several cancer indications, which should result in annual peak sales of more than $10 billion.
The majority of Bristol's late-stage pipeline focuses on rare diseases, immunology, and cancer, where the Food and Drug Administration aggressively approves drugs and typically holds strong pricing power.
Truist Securities
2025-01-08
Price Target
$62 → $65
Upside
+14.33%
B of A Securities
2024-12-10
Price Target
$63
Upside
+8.56%
Leerink Partners
2024-11-12
Price Target
$55 → $73
Upside
+23.59%